Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HCWB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Restatement (new) — Q1 2026 financial statements should no longer be relied upon due to EPS calculation error
- Material Weakness (new) — Internal controls over technical accounting for complex warrant instruments operated ineffectively
HCW Biologics restates Q1 2026 financials, notes it has identified material weaknesses in internal control over financial reporting in the past and may do so again in controls
Filed August 14, 2026 · Period ending August 10, 2026 · ~1 min read
Key Changes
-
high
Q1 2026 EPS overstated by $0.80/share ($2.19 reported vs. $1.39 corrected) due to misapplication of two-class method; company failed to allocate 36.7% of earnings to participating warrants
Item 4.02 — Non-Reliance on Previously Issued Financial Statements verify on EDGAR → -
high
Material weakness identified in technical accounting controls over complex warrant instruments and financing transactions; controls failed to evaluate contractual provisions at sufficient precision
Item 4.02 — Non-Reliance on Previously Issued Financial Statements verify on EDGAR → -
medium
Company will file amended 10-Q to restate Q1 2026 financials; implementing enhanced technical accounting review procedures and improved coordination with legal counsel
Item 4.02 — Non-Reliance on Previously Issued Financial Statements verify on EDGAR →
Summary
HCW Biologics disclosed that its Q1 2026 financial statements contain a material error requiring restatement. The company overstated earnings per share by $0.80 per share (reporting $2.19 instead of the correct $1.39) because it failed to properly apply the two-class method for calculating EPS.
Specifically, the company allocated 100% of undistributed earnings to common stock when it should have allocated only 63.3% to common stock and 36.7% to participating warrants with non-forfeitable dividend rights. The error exposed a material weakness in the company's internal controls over financial reporting.
Management concluded that technical accounting review controls for complex warrant instruments and financing transactions were not operating effectively at a sufficient level of precision. The company is implementing remediation measures including enhanced technical accounting review procedures and improved coordination with legal counsel. Investors should watch for the amended 10-Q filing and assess whether the control weakness affects confidence in other reported figures involving complex instruments.
Section-by-Section Diff
Event · Item 4.02 — Non-Reliance on Previously Issued Financial Statements
HCW Biologics restates Q1 2026 financials due to EPS calculation error; notes it has identified material weaknesses in internal control over financial reporting in the past and may do so again in technical accounting controls.
Added in current filing · verify on EDGAR →
the Company’s previously issued unaudited condensed financial statements as of and for the three months ended March 31, 2026, included in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 14, 2026 (the “Original Form 10-Q”), should no longer be relied upon. The Company intends to file an amendment to the Original Form 10-Q on Form 10-Q/A (the “Form 10-Q/A”) to restate the affected unaudited condensed financial statements and related disclosures for the three months ended March 31, 2026.
The Audit Committee concluded that the Q1 2026 financial statements filed in May 2026 should no longer be relied upon and will be restated. The company will file an amended 10-Q to correct the financial statements and related disclosures.
Added in current filing · verify on EDGAR →
The non-reliance conclusion described above resulted from the identification of an error in the Company’s application of the two-class method for calculating earnings per share (“EPS”). Specifically, the Company did not appropriately allocate undistributed earnings between Common Stock and participating securities with non-forfeitable dividend rights. Management determined that these errors constituted a material misstatement of EPS.
The restatement stems from an error in applying the two-class method for calculating EPS. The company failed to properly allocate undistributed earnings between common stock and participating securities with non-forfeitable dividend rights, resulting in a material misstatement of EPS.
Added in current filing · verify on EDGAR →
After giving effect to the Company’s reverse stock split effective on June 30, 2026, the Company had 904,312 weighted-average shares of Common Stock outstanding and had outstanding participating warrants which may be exercised for 524,501 shares of Common Stock as of March 31, 2026. On a post-split basis, as a result of the misapplication of the two-class method, the Company reported basic and diluted EPS of $2.19 per share, an overstatement of $0.80 per share, caused by applying a 100% allocation of undistributed earnings to the weighted average shares outstanding; however, the Company should have allocated approximately 63.3% of the applicable undistributed earnings to Common Stock and approximately 36.7% to the participating securities.
The company originally reported Q1 2026 EPS of $2.19 per share (post-split basis), which was overstated by $0.80 per share. The error occurred because the company allocated 100% of undistributed earnings to common stock, when it should have allocated approximately 63.3% to common stock and 36.7% to participating securities. The corrected EPS will be $1.39 per share.
Added in current filing · verify on EDGAR →
Management evaluated the effect of the error and restatement on the Company’s disclosure controls and procedures and internal control over financial reporting and concluded that a material weakness existed related to the ineffective operation of the Company’s technical accounting review control over complex warrant instruments and financing transactions, including the evaluation of relevant contractual provisions and related legal interpretations, at a sufficient level of precision.
Management notes it has identified material weaknesses in internal control over financial reporting in the past and may do so again related to technical accounting review controls for complex warrant instruments and financing transactions. The controls were not operating effectively at a sufficient level of precision to properly evaluate contractual provisions and related legal interpretations.
Added in current filing · verify on EDGAR →
Management is implementing remediation measures, including enhanced technical accounting review procedures, and improved coordination with legal counsel and other advisors, as appropriate.
The company is implementing remediation measures to address the material weakness, including enhanced technical accounting review procedures and improved coordination with legal counsel and other advisors.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 17, 2026 · How we verify